# Generation of JC Polyoma Pseudovirus for High-Throughput Measurement of Neutralizing Antibodies

**Authors:** Mami Matsuda, Tian-Cheng Li, Akira Nakanishi, Kazuo Nakamichi, Makoto Saito, Tadaki Suzuki, Tomokazu Matsuura, Masamichi Muramatsu, Tetsuro Suzuki, Yoshiharu Miura, Ryosuke Suzuki

PMC · DOI: 10.3390/diagnostics14030311 · Diagnostics · 2024-01-31

## TL;DR

Researchers developed a new method to measure antibodies against JC polyomavirus, which is linked to a serious brain disease in immunocompromised individuals.

## Contribution

A novel high-throughput assay system using JCPyV pseudoviruses for measuring neutralizing antibodies is developed and validated.

## Key findings

- A reporter-based neutralization assay was established for JCPyV and BKPyV with no cross-reactivity confirmed.
- Antibody titers from healthy donors, MS patients, and HIV-positive patients were compared using ELISA and pseudovirus assays.
- A positive correlation was found between neutralization titers and antibody levels measured by JCPyV-like particle ELISA.

## Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system (CNS) caused by reactivation of dormant JC polyomavirus (JCPyV). PML was mainly observed in immunocompromised individuals, such as HIV-positive patients, autoimmune disease patients, and cancer patients. Given that the presence of anti-JCPyV antibodies in serum is a risk indicator for PML development, it is essential to monitor anti-JCPyV antibody levels. In the present study, we established reporter-based single-infection neutralization assays for JCPyV and the genetically similar BK polyoma virus (BKPyV). We then confirmed the lack of cross-reactivity between the two viruses using test sera obtained from mice immunized with plasmids encoding the JCPyV or BKPyV capsid. Next, we compared neutralization antibody titers in sera from healthy donors, patients with multiple sclerosis (MS), and HIV-positive patients using an in-house enzyme-linked immunosorbent assay (ELISA) with JCPyV-like particles (virus-like particles; VLPs). A positive correlation was demonstrated between the neutralization titer (75% infectious concentration; IC75) against JCPyV and the antibody titer obtained by VLP-based JCPyV ELISA. This assay system may be applied to detect antibodies against other PyVs by generation of pseudoviruses using the respective capsid expression plasmids, and is expected to contribute to the surveillance of PyV as well as basic research on these viruses.

## Linked entities

- **Diseases:** Progressive multifocal leukoencephalopathy (MONDO:0016318), multiple sclerosis (MONDO:0005301)
- **Species:** Homo sapiens (taxon 9606), Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** CNS (MESH:D002493), autoimmune disease (MESH:D001327), cancer (MESH:D009369), JC Polyoma (MESH:D007968), demyelinating disease of the central nervous system (MESH:D020278), MS (MESH:D009103)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676], Mus musculus (house mouse, species) [taxon 10090], JC polyomavirus (no rank) [taxon 10632], Betapolyomavirus hominis (species) [taxon 1891762]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10855674/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10855674/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC10855674/full.md

---
Source: https://tomesphere.com/paper/PMC10855674